Procleix ArboPlex Assay® da Grifols recebe a marca CE, o primeiro e único NAT 4 em 1 para o rastreio de arbovírus
April 04, 2024 04:00 ET
|
Grifols, S.A.
O teste de ácido nucleico in vitro da Grifols deteta quatro tipos de arbovírus, ajudando a reduzir o risco de infeções transmitidas por transfusãoOs arbovírus são uma ameaça emergente crescente, com...
Procleix ArboPlex Assay® di Grifols, primo e unico test NAT 4-in-1 per lo screening degli arbovirus, riceve il marchio CE
April 04, 2024 04:00 ET
|
Grifols, S.A.
Il test NAT in vitro di Grifols rileva quattro tipi di arbovirus, contribuendo a ridurre il rischio di infezioni trasmesse tramite trasfusioneGli arbovirus sono una minaccia emergente in crescita,...
Grifols Procleix ArboPlex Assay® erhält die CE-Zertifizierung – der erste und einzige 4-in-1-Nukleinsäuretest zum Nachweis von Arboviren
April 04, 2024 04:00 ET
|
Grifols, S.A.
Der In-vitro-Nukleinsäuretest von Grifols weist vier Arten von Arboviren nach und trägt dazu bei, das Risiko transfusionsbedingter Infektionen zu verringernArboviren stellen eine wachsende Bedrohung...
Le test Procleix ArboPlex Assay® de Grifols, test de Dépistage Génomique Viral 4-en-1 destiné au dépistage des arbovirus, reçoit le marquage CE
April 04, 2024 04:00 ET
|
Grifols, S.A.
Le test d’acide nucléique in vitro de Grifols détecte quatre types d’arbovirus, contribuant ainsi à la diminution du risque d’infections transmises par transfusion*Les arbovirus constituent une menace...
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
April 04, 2024 04:00 ET
|
Grifols, S.A.
Grifols’ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in...
EnWave Signs Technology Evaluation and License Option Agreement with Food Company Led by Michelin Star Chef
April 02, 2024 09:00 ET
|
EnWave Corporation
VANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) today announced that it has signed a Technology Evaluation and...
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
April 02, 2024 08:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
March 28, 2024 07:00 ET
|
Xilio Therapeutics, Inc.; Gilead Sciences, Inc.
-- Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers -- FOSTER CITY, Calif....
EBC Financial Group (Cayman) Limited, 케이맨 제도 통화당국CIMA로부터 승인 및 규제
March 28, 2024 06:53 ET
|
EBC Financial Group
홍콩, March 28, 2024 (GLOBE NEWSWIRE) -- 최근, EBC 금융 그룹 (EBC 그룹 또는 EBC) 는 케이맨 제도 통화 당국 (CIMA)로부터 라이선스를 획득했습니다. 레퍼런스 번호는 2038223입니다. EBC 그룹은 전 세계의 주요 금융 법적 관할 지역에서 승인 및 감독을 받았으며, CIMA 라이선스는 FCA 와ASIC...
EBC Financial Group、ケイマン諸島金融フルライセンスを取得
March 28, 2024 06:53 ET
|
EBC Financial Group
HONG KONG, March 28, 2024 (GLOBE NEWSWIRE) -- EBC Financial Group (以下、当社）は、ケイマン諸島の子会社であるEBC Financial...